#United States #Guangzhou #FDA Approval #Bio-Thera Solutions #golimumab

Bio-Thera Solutions' Landmark FDA Approval for Golimumab Biosimilars

On May 18, 2026, Bio-Thera Solutions, a prominent biopharmaceutical firm based in Guangzhou, China, announced that two of its golimumab biosimilars, IMMGOLIS and IMMGOLIS INTRI, received marketing authorization from the U.S. Food and Drug Administration (FDA). This groundbreaking approval positions Bio-Thera as the first company to offer FDA-approved biosimilars to Simponi® and Simponi Aria®, both known for their efficacy in treating chronic autoimmune conditions.

What Are Golimumab Biosimilars?

Golimumab is a monoclonal antibody that specifically targets tumor necrosis factor alpha (TNF-α), a key pro-inflammatory cytokine that plays an essential role in the development of autoimmune diseases like rheumatoid arthritis (RA) and ulcerative colitis (UC). By inhibiting TNF-α, golimumab effectively reduces various inflammatory markers such as C-reactive protein (CRP) and interleukin 6 (IL-6). The newly introduced biosimilars, IMMGOLIS and IMMGOLIS INTRI, are designed to provide similar therapeutic benefits at a potentially lower cost, making treatment more accessible to patients.

Treatment Options Available

IMMGOLIS is approved for the treatment of adult patients with moderately to severely active RA in combination with methotrexate. It is also indicated for treating adults suffering from moderately to severely active UC. On the other hand, IMMGOLIS INTRI is specified for adults dealing with moderately to severely active RA alongside methotrexate.

Both products represent a significant advancement in the biosimilar landscape, enhancing treatment options for patients who may struggle with the high costs of branded biologics. This is particularly crucial given the increasing prevalence of autoimmune diseases in the United States and globally.

Strategic Partnerships Enhance Commercialization

Bio-Thera Solutions has partnered with Accord BioPharma, a division of Intas Pharmaceuticals, which specializes in oncology, immunology, and CNS therapies, to distribute these new biosimilars in the U.S. Under the exclusive commercialization agreement, Bio-Thera assumes responsibility for the manufacturing and developmental processes of IMMGOLIS and IMMGOLIS INTRI, while Accord BioPharma focuses on bringing these essential therapies to the market.

Dr. Shengfeng Li, CEO of Bio-Thera, expressed his pride in achieving this milestone, stating, "We are excited to support Accord BioPharma's commercialization efforts to provide affordable biosimilars to patients living with chronic and debilitating autoimmune conditions."

Chrys Kokino, President of Accord BioPharma, emphasized the importance of this collaboration, saying, "This agreement strengthens our biosimilar pipeline, which is crucial for our growth strategy. We are committed to increasing patient access to these biologic medicines, which have previously been out of reach for many due to high costs."

The Future of Biosimilars

The approval of IMMGOLIS and IMMGOLIS INTRI highlights the potential of biosimilars to transform the treatment landscape for autoimmune disorders. With more than 15 biosimilars already marketed by Intas, the partnership between Bio-Thera and Accord stands as a pioneering example of how collaboration can expand treatment possibilities and offer hope to patients battling chronic illnesses.

As the healthcare industry continues to evolve, the demand for affordable therapeutic options will only increase, making the success of these biosimilars pivotal in reshaping the biosimilar landscape. Bio-Thera's leadership in developing innovative therapies and its commitment to quality assurance have set a new standard in the biopharmaceutical sector, allowing more patients to access the treatments they desperately need.

For more information about Bio-Thera Solutions and its innovative products, please visit their official website or follow them on social media channels, including X and WeChat.